Functional capacity in rheumatoid arthritis patients: comparison between Spanish and Brazilian sample
- 127 Downloads
The main objective of this study is to compare Spanish and Brazilian self-reported health-related functional capacity in patients with rheumatoid arthritis (RA). 197 patients diagnosed with RA were studied in Spain (n = 127) and Brazil (n = 70). Pain (Visual analog scale) and functional capacity (Health Assessment Questionnaire/HAQ) were assessed. Patients were questioned about regular exercise practice. Comparisons between groups were performed with Chi-square tests and Student t test. Pearson’s correlation coefficient and linear regression models were used to analyze the associations. Brazilian patients were younger (p = 0.013), had worse levels of pain (p = 0.001) and a trend to experience worse functional capacity (p = 0.057) than Spanish ones. Spanish RA patients had higher body mass index (BMI) (p = 0.019) and longer disease duration (p = 0.001). Also, a higher percentage of subjects with RA from the Spanish cohort had been elected to take early retirement when compared with Brazilian patients (p = 0.010). Spanish RA patients had received more drugs than Brazilians (oral corticosteroids p = 0.010, Leflunomide p = 0.023, Methotrexate p = 0.072, non-steroidal anti-inflammatory drugs p = 0.064, biologic therapies p = 0.001). The functional capacity (HAQ) was correlated with age (p = 0.001), disease duration (p = 0.001), age at diagnosis (p = 0.001), pain (p = 0.001) and BMI (p = 0.001) in Spanish patients. In Brazilian, these correlations were only found with disease duration (p = 0.004) and pain (p = 0.001). In conclusion, our data suggest a better management of RA in Spanish when compared with Brazilians. Even with less pain and functional capacity, they receive more drug treatment and a higher percentage of them are retired early.
KeywordsFunctional capacity Rheumatoid arthritis Brazil Spain
The authors thank the staff and patients of Hospital Xeral-Calde, Lugo (Spain). We especially thank to Dr. Amalia Sanchez-Andrade, Dr. José Alberto Miranda Filloy, Dr. Tomás Ramón Vázquez Rodríguez members of the Rheumatology Division and Mrs. Susana Escandón nurse from the Rheumatology Division of Hospital Xeral-Calde, Lugo (Spain) for the valuable help in the recruitment of the patients. We also thank to Brazilian National Research and Development Council (CNPq) for supporting Dr. Ide fellowship.
- 1.Akbulut Aktekin L, Eser F, Malhan S, Oksüz E, Keskin D, Bodur H (2009) A comparison of four different HRQoL generic questionnaire in five different patient groups. Rheumatol Int (epub ahead of print)Google Scholar
- 14.DC C (1994) Centers for Diseases Control and Prevention. Arthritis prevalence and activity limitations, United States, 1990. MMWR Morb Mortal Wkly Rep 43:433–438Google Scholar
- 17.Eurostat (2007) Europe in figures. Eurostat Yearbook 2006–2007. Naciones UnidasGoogle Scholar
- 18.Rubio-Terrés C, Ordovás Baines JP, Pla Poblador R, Martínez Nieto C, Sánchez Garre MJ, Rosado Souvirón MA et al (2007) Grupo de Investigadores del Estudio PRAXIS. Use and cost of biological disease-modifying anti-rheumatic drugs in Spain (PRAXIS study). Farm Hosp 31:78–92CrossRefPubMedGoogle Scholar
- 21.Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, Piñeiro A, Garcia-Porrua C, Miranda-Filloy JA, Ollier WE, Martin J, Llorca J (2007) HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 57:125–132CrossRefPubMedGoogle Scholar
- 22.Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48CrossRefPubMedGoogle Scholar
- 27.Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR, Diaz-Varela N, Garcia-Quiroga H, Gonzalez-Gay MA (2008) Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum 59:1821–1824CrossRefPubMedGoogle Scholar
- 31.Monteiro RDC, Zanini AC (2008) Análise de custo do tratamento medicamentoso da artrite reumatóide. Rev Bras Cienc Farm 44:25–33Google Scholar